Skip to main content
TipRanks
Go Ultimate75% OFF

Ascelia Pharma AB (7ZA) AI Stock Analysis

2 Followers
DE:7ZA

Ascelia Pharma AB

(Frankfurt:7ZA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low leverageVery low debt reduces refinancing pressure and interest burden while preserving financial flexibility. Compared with a highly leveraged biotech, Ascelia has less obligation to divert future capital toward debt service, leaving more capacity for clinical development and regulatory work if financing remains available.
Negative Factors
No established revenueAscelia has not yet demonstrated commercial demand or revenue scale, leaving its business model dependent on successful development and approval of Orviglance. Until product sales begin, fixed research and operating costs cannot be absorbed by recurring revenue, keeping execution risk elevated.

Ascelia Pharma AB (7ZA) vs. iShares MSCI Germany ETF (EWG)

-100%-75%-50%-25%0%25%50%DE:7ZA-82.81%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 6.97M
Dividend Yield
―
Average Volume (3M)
13.00K
Price to Earnings (P/E)
-1.3
Beta (1Y)
55.11
Revenue Growth
―
EPS Growth
49.02%
Country
Germany
Employees
10
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Ascelia Pharma AB Business Overview & Revenue Model

Company Description

Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trial...

Ascelia Pharma AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:7ZA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA61NeutralSEK 391.34M2.0463.09%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ONCOSE:ONCO44NeutralSEK 763.50M-2.81――65.37%43.28%
SE:BINVSE:BINV43NeutralSEK 191.82M-0.39-128.54%―-83.67%-50.29%
SE:IMMUSE:IMMU39UnderperformSEK 276.26M-2.43-19.14%――13.06%
SE:ONCOZSE:ONCOZ39UnderperformSEK 89.57M-1.38-970.69%―115.26%-230.43%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:7ZASE:BINVSE:ONCOSE:ONCOZSE:IMMUSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:7ZA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:7ZAAscelia Pharma AB0.04-0.22-83.14%
SE:BINVBioInvent International AB2.92-26.98-90.25%
SE:ONCOOncopeptides AB1.77-3.13-63.86%
SE:ONCOZOncoZenge AB3.25-1.68-34.07%
SE:IMMUImmunicum AB4.36-1.30-23.06%
SE:CANTACantargia AB1.39-2.06-59.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.